相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ketamine effects on default mode network activity and vigilance: A randomized, placebo-controlled crossover simultaneous fMRI/EEG study
Norman Zacharias et al.
HUMAN BRAIN MAPPING (2020)
Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression
Elia E. Acevedo-Diaz et al.
JOURNAL OF AFFECTIVE DISORDERS (2020)
Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Friederike Holze et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression
Meghan Hibicke et al.
ACS CHEMICAL NEUROSCIENCE (2020)
Psychedelics and Psychedelic-Assisted Psychotherapy
Collin M. Reiff et al.
AMERICAN JOURNAL OF PSYCHIATRY (2020)
Modulation of amygdala reactivity following rapidly acting interventions for major depression
Joana R. A. Loureiro et al.
HUMAN BRAIN MAPPING (2020)
The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review
David S. Mathai et al.
JOURNAL OF AFFECTIVE DISORDERS (2020)
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)
Maurizio Fava et al.
MOLECULAR PSYCHIATRY (2020)
GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions
Danielle M. Gerhard et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression
Lea J. Mertens et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2020)
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
Gabrielle Agin-Liebes et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2020)
Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment
Christoph Kraus et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation
Jessica R. Gilbert et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2020)
Some Comments on Psychedelic Research
Alan F. Schatzberg
AMERICAN JOURNAL OF PSYCHIATRY (2020)
Medial PFC AMPA receptor and BDNF signaling are required for the rapid and sustained antidepressant-like effects of 5-HT1A receptor stimulation
Kenichi Fukumoto et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin
N. L. Mason et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
Nicole Leite Galvao-Coelho et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2020)
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
Fernanda Palhano-Fontes et al.
PSYCHOLOGICAL MEDICINE (2019)
Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study
Allison C. Nugent et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2019)
Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder
Sabine Aust et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2019)
(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses
Panos Zanos et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
S-Ketamine Reverses Hippocampal Dendritic Spine Deficits in Flinders Sensitive Line Rats Within 1 h of Administration
Giulia Treccani et al.
MOLECULAR NEUROBIOLOGY (2019)
Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments
Ronald S. Duman et al.
NEURON (2019)
A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms
M. V. Uthaug et al.
PSYCHOPHARMACOLOGY (2019)
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
R. L. Carhart-Harris et al.
PHARMACOLOGICAL REVIEWS (2019)
Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
Kenji Hashimoto
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2019)
The influence of ketamine on drug discovery in depression
Christoph Kraus et al.
DRUG DISCOVERY TODAY (2019)
Cortical dynamics during psychedelic and anesthetized states induced by ketamine
Duan Li et al.
NEUROIMAGE (2019)
Effects of ketamine treatment on suicidal ideation: a qualitative study of patients' accounts following treatment for depression in a UK ketamine clinic
Karen Lascelles et al.
BMJ OPEN (2019)
Classical psychedelics for the treatment of depression and anxiety: A systematic review
Silvia Muttoni et al.
JOURNAL OF AFFECTIVE DISORDERS (2019)
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Bashkim Kadriu et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2019)
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
Matthew W. Johnson et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial
Raissa Nobrega de Almeida et al.
FRONTIERS IN PSYCHOLOGY (2019)
A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms
Leah M. Fleming et al.
NEUROIMAGE-CLINICAL (2019)
Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
R. N. Moda-Sava et al.
SCIENCE (2019)
Role of 5-HT1A Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine
Kenichi Fukumoto et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2018)
Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling
L. Cavalleri et al.
MOLECULAR PSYCHIATRY (2018)
Psychiatry & the psychedelic drugs. Past, present & future
James J. H. Rucker et al.
NEUROPHARMACOLOGY (2018)
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
R. L. Carhart-Harris et al.
PSYCHOPHARMACOLOGY (2018)
Effects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Lindsay P. Cameron et al.
ACS CHEMICAL NEUROSCIENCE (2018)
Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration
Jennifer W. Evans et al.
BIOLOGICAL PSYCHIATRY (2018)
Subanaesthetic ketamine and altered states of consciousness in humans
P. E. Vlisides et al.
BRITISH JOURNAL OF ANAESTHESIA (2018)
A brain network model for depression: From symptom understanding to disease intervention
Bao-Juan Li et al.
CNS NEUROSCIENCE & THERAPEUTICS (2018)
Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale
Gerrit I. van Schalkwyk et al.
JOURNAL OF AFFECTIVE DISORDERS (2018)
Mechanisms of ketamine action as an antidepressant
P. Zanos et al.
MOLECULAR PSYCHIATRY (2018)
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
Matthew W. Johnson et al.
NEUROPHARMACOLOGY (2018)
Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans
David J. Heal et al.
NEUROPHARMACOLOGY (2018)
The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects
Chadi G. Abdallah et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy
Allie J. Widman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
The hidden therapist: evidence for a central role of music in psychedelic therapy
Mendel Kaelen et al.
PSYCHOPHARMACOLOGY (2018)
Psychedelics Promote Structural and Functional Neural Plasticity
Calvin Ly et al.
CELL REPORTS (2018)
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Leor Roseman et al.
FRONTIERS IN PHARMACOLOGY (2018)
Pharmacological fMRI: Effects of subanesthetic ketamine on resting-state functional connectivity in the default mode network, salience network, dorsal attention network and executive control network
Felix Mueller et al.
NEUROIMAGE-CLINICAL (2018)
Ketamine normalizes brain activity during emotionally valenced attentional processing in depression
Jessica L. Reed et al.
NEUROIMAGE-CLINICAL (2018)
Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study
Chen Mu-Hong et al.
PSYCHIATRY RESEARCH (2018)
Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews
Rafael G. dos Santos et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate Gyrus
Rafael Vitor Lima da Cruz et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2018)
Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor
Katrin H. Preller et al.
ELIFE (2018)
Psychedelics as anti-inflammatory agents
Thomas W. Flanagan et al.
INTERNATIONAL REVIEW OF PSYCHIATRY (2018)
Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects
G. M. I. Chowdhury et al.
MOLECULAR PSYCHIATRY (2017)
Ketamine Treatment and Global Brain Connectivity in Major Depression
Chadi G. Abdallah et al.
NEUROPSYCHOPHARMACOLOGY (2017)
Ketamine and aminoguanidine differentially affect Bdnf and Mtor gene expression in the prefrontal cortex of adult male rats
Vitor Silva Pereira et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
Administration of ketamine for unipolar and bipolar depression
Christoph Kraus et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2017)
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Robin L. Carhart-Harris et al.
NEUROPSYCHOPHARMACOLOGY (2017)
Psychedelic Drugs in Biomedicine
Evan J. Kyzar et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin
Michael M. Schartner et al.
SCIENTIFIC REPORTS (2017)
Ketamine and Imipramine Reverse Transcriptional Signatures of Susceptibility and Induce Resilience-Specific Gene Expression Profiles
Rosemary C. Bagot et al.
BIOLOGICAL PSYCHIATRY (2017)
Resting-state Network-specific Breakdown of Functional Connectivity during Ketamine Alteration of Consciousness in Volunteers
Vincent Bonhomme et al.
ANESTHESIOLOGY (2016)
Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans
Marta Valle et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression A SPECT Study
Rafael Faria Sanches et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2016)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Ronald S. Duman et al.
NATURE MEDICINE (2016)
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Robin L. Carhart-Harris et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Effects of Ketamine on Resting-State EEG Activity and Their Relationship to Perceptual/Dissociative Symptoms in Healthy Humans
Sara de la Sallel et al.
FRONTIERS IN PHARMACOLOGY (2016)
Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain
David A. Martin et al.
EBIOMEDICINE (2016)
Ketamine-Induced Modulation of the Thalamo-Cortical Network in Healthy Volunteers As a Model for Schizophrenia
Anna Hoeflich et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2015)
Ketamine ameliorates depressive-like behaviors and immune alterations in adult rats following maternal deprivation
Gislaine Z. Reus et al.
NEUROSCIENCE LETTERS (2015)
Acute Biphasic Effects of Ayahuasca
Eduardo Ekman Schenberg et al.
PLOS ONE (2015)
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report
Flavia de L. Osorio et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2015)
BDNF Release Is Required for the Behavioral Actions of Ketamine
Ashley E. Lepack et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2015)
Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression
E. Drewniany et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2015)
The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network
Fernanda Palhano-Fontes et al.
PLOS ONE (2015)
Enhanced Repertoire of Brain Dynamical States During the Psychedelic Experience
Enzo Tagliazucchi et al.
HUMAN BRAIN MAPPING (2014)
Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression
C. N. Haile et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
Peter Gasser et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2014)
Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia
David A. Martin et al.
NEUROPHARMACOLOGY (2014)
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
James W. Murrough et al.
BIOLOGICAL PSYCHIATRY (2013)
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder
Wallace C. Duncan et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
Broadband Cortical Desynchronization Underlies the Human Psychedelic State
Suresh D. Muthukumaraswamy et al.
JOURNAL OF NEUROSCIENCE (2013)
Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on α Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations
Michael Kometer et al.
JOURNAL OF NEUROSCIENCE (2013)
Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: Role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis
Andrea de Bartolomeis et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
Default Mode Network Activity and Connectivity in Psychopathology
Susan Whitfield-Gabrieli et al.
ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 8 (2012)
Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients
Gonzalo Laje et al.
BIOLOGICAL PSYCHIATRY (2012)
Synaptic Potentiation Is Critical for Rapid Antidepressant Response to Ketamine in Treatment-Resistant Major Depression
Brian R. Cornwell et al.
BIOLOGICAL PSYCHIATRY (2012)
Brain-Derived Neurotrophic Factor Val66Met Allele Impairs Basal and Ketamine-Stimulated Synaptogenesis in Prefrontal Cortex
Rong-Jian Liu et al.
BIOLOGICAL PSYCHIATRY (2012)
Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial
Carlos A. Zarate et al.
BIOLOGICAL PSYCHIATRY (2012)
Global Connectivity of Prefrontal Cortex Predicts Cognitive Control and Intelligence
Michael W. Cole et al.
JOURNAL OF NEUROSCIENCE (2012)
Towards a glutamate hypothesis of depression An emerging frontier of neuropsychopharmacology for mood disorders
Gerard Sanacora et al.
NEUROPHARMACOLOGY (2012)
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Robin L. Carhart-Harris et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Charles S. Grob et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Anita E. Autry et al.
NATURE (2011)
The double edged sword of neural plasticity: Increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover
Igor Branchi
PSYCHONEUROENDOCRINOLOGY (2011)
A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression
Nancy Diazgranados et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
OPINION The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Franz X. Vollenweider et al.
NATURE REVIEWS NEUROSCIENCE (2010)
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Nanxin Li et al.
SCIENCE (2010)
Brain-Derived Neurotrophic Factor and Initial Antidepressant Response to an N-Methyl-D-Aspartate Antagonist
Rodrigo Machado-Vieira et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression
Bradley N. Gaynes et al.
PSYCHIATRIC SERVICES (2009)
Cellular mechanisms underlying the antidepressant effects of ketamine:: Role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors
Sungho Maeng et al.
BIOLOGICAL PSYCHIATRY (2008)
Human hallucinogen research: guidelines for safety
M. W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
AMPA receptor involvement in 5-hydroxytryptamine(2A) receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes
Ce Zhang et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus
Leda S. B. Garcia et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Is it time to reassess the BDNF hypothesis of depression?
J. O. Groves
MOLECULAR PSYCHIATRY (2007)
NMDA receptor hypofunction produces opposite effects on prefrontal cortex Interneurons and pyramidal neurons
Houman Homayoun et al.
JOURNAL OF NEUROSCIENCE (2007)
Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex
Jean-Claude Beique et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens
Florence Razoux et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior
Javier Gonzalez-Maeso et al.
NEURON (2007)
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
Carlos A. Zarate et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Hallucinogen-induced UP states in the brain slice of rat-prefrontal cortex: Role of glutamate spillover and NR2B-NMDA receptors
Evelyn K. Lambe et al.
NEUROPSYCHOPHARMACOLOGY (2006)
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
R. R. Griffiths et al.
PSYCHOPHARMACOLOGY (2006)
Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex
JW Muschamp et al.
BRAIN RESEARCH (2004)
The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats
JL Scruggs et al.
NEUROSCIENCE LETTERS (2003)
In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors:: Relationship to thalamocortical afferents
MV Puig et al.
CEREBRAL CORTEX (2003)
Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration
CD Nichols et al.
MOLECULAR BRAIN RESEARCH (2003)
A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain
CD Nichols et al.
NEUROPSYCHOPHARMACOLOGY (2002)
Antidepressant effects of ketamine in depressed patients
RM Berman et al.
BIOLOGICAL PSYCHIATRY (2000)
分享论文
